main content start
How do you like the content?
Breast Cancer 8m 50s

Immunotherapy of Early Breast Cancer

Published 30 Aug 2022
I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy showing doubling of the estimated pCR rates for both HR-positive / Her 2-negative and triple-negative breast cancer.
In the confirmatory Keynote 522 trial : Pembrolizumab added to Neoadjuvant chemotherapy significantly improved PCR , EFS for early-stage Triple Negative Breast Cancer and was subsequently approved by FDA in July 2021 for high-risk early stage TNBC with chemotherapy as neoadjuvant treatment and then to be continued as single agent adjuvant treatment after surgery. For more information refer to a clinical practice guideline on Immunotherapy for treatment of Early Breast Cancer published by Society of Immunotherapy of Cancer (SITC)
keynote -522 immunotherapy early breast cancer

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Perks of registering with us
Access to Online/Offline Events
Personalized Content
Access to all Features
Hi, can I help?
Chat SupportX
Support Team
Hello, how can I help you today?
Please select one of the below options.

Find Information

Unable to Login or Register

Want to share feedback